Drugs / AV2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02346227 Comparator | Jan 2015 → Aug 2018 | dysplasia of cervix, human papilloma virus infection | Jean-Pierre Van geertruyden | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02346227 ↗ |
| Modality | Other / unclassified | “Antiviral AV2® is a mixture of natural essential oils (eugenol, carvone, nerolidol, geraniol) in olive oil, and has a broad spectrum anti-viral activity.” PMID 31193477 ↗ May 2019 |
| Route | Topical | “It is administered as a topical spray to the cervix” NCT02346227 ↗ |